Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Invested Capital: 2021-2025

Historic Invested Capital for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $535.4 million.

  • Kiniksa Pharmaceuticals International's Invested Capital rose 22.51% to $535.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $535.4 million, marking a year-over-year increase of 22.51%. This contributed to the annual value of $438.4 million for FY2024, which is 0.09% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Invested Capital of $535.4 million as of Q3 2025, which was up 8.16% from $495.0 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Invested Capital high stood at $535.4 million for Q3 2025, and its period low was $153.5 million during Q2 2022.
  • Moreover, its 3-year median value for Invested Capital was $437.0 million (2024), whereas its average is $443.3 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Invested Capital slumped by 38.59% in 2022 and then soared by 168.19% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Invested Capital (Quarterly) stood at $185.0 million in 2021, then surged by 114.09% to $396.1 million in 2022, then increased by 10.78% to $438.8 million in 2023, then dropped by 0.09% to $438.4 million in 2024, then grew by 22.51% to $535.4 million in 2025.
  • Its last three reported values are $535.4 million in Q3 2025, $495.0 million for Q2 2025, and $457.5 million during Q1 2025.